ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?

Mithu Maheswaranathan, MD  |  September 9, 2025

A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabbiopsyCAR-T cell therapyLupus nephritisMycophenolateobinutuzumabProteinuriaSLE Resource Centervoclosporin

How the Experts Treat Sjögren’s Disease

Samantha C. Shapiro, MD  |  August 26, 2025

With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSjögren’s Disease Tagged with:Clinical Practice GuidelinesDry eyeDry MouthfatigueHYDROXYCHLOROQUINEInterstitial Lung DiseaseMethotrexateneuropathyshared decision makingSjögren’s Disease supplement

Encourage Physical Activity During Rheumatic Disease Awareness Month

Vanessa Caceres  |  August 25, 2025

This year’s Rheumatic Disease Awareness Month encourages rheumatology professionals to collaborate with patients on physical activity routines that benefit their health.

Filed under:Conditions Tagged with:Exercisepatient careRDAMRheumatic Disease Awareness Month (RDAM)

The Rheumatic Dangers of Wildfire Smoke

Deborah Levenson  |  August 7, 2025

A recent study in A&R identifies an association between air pollutants, including fire smoke particulate matter, & both rheumatoid arthritis (RA) & RA-associated interstitial lung disease.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:air pollutionenvironmental factorinterstitial lung disease (ILD)lungsRA Resource CenterRisk Factorswildfire smoke

Emerging Therapies for Antiphospholipid Syndrome, an Antibody-Mediated Disease

Katie Robinson  |  August 6, 2025

A recent A&R review explores innovative, emerging therapies for the currently incurable, antibody-mediated disease antiphospholipid syndrome.

Filed under:Biologics/DMARDsConditionsDrug UpdatesGuidanceOther Rheumatic ConditionsResearch Rheum Tagged with:AntibodiesanticoagulantAntiphospholipid syndromeautoantibodiesB cellsCAR-T cell therapyHYDROXYCHLOROQUINEImmunology Insightslupus anticoagulantPathogenesisrituximabthrombosiswarfarin

Key Research in Vasculitis Encapsulated

Philip Seo, MD, MHS  |  August 6, 2025

Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch RheumVasculitis Tagged with:AAV FocusRheumACR Convergence 2024DADA2eosinophilic granulomatosis with polyangiitis (EGPA)Giant Cell ArteritisGlucocorticoidsgranulomatosis with polyangiitisIgG4 related diseaseinebilizumabInterleukinJAK inhibitormepolizumabupadacitinibVasculitis

Editor's Pick

Understanding Immunologic Complications of Measles

Ruth Jessen Hickman, MD  |  August 6, 2025

As measles outbreaks increase domestically & internationally, while vaccination uptake decreases in the U.S., experts discuss treatment recommendations & the immunologic consequences of measles infections in patients with rheumatic diseases.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGuidance Tagged with:BiologicsEditor's PickImmunityimmunocompromisedimmunosuppressioninfectious diseaselive vaccineMeaslesMMRoutbreakspublic healthvaccinationvaccine hesitancy

Results for Novel, Glucocorticoid-Sparing Treatment for Patients with PMR

Arthritis & Rheumatology  |  July 31, 2025

A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.

Filed under:ConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:ABBV-154glucocorticoid receptor modulatorGlucocorticoidspatient carePMRPolymyalgia Rheumatica

Highlights from the European Congress of Internal Medicine

Vanessa Caceres  |  July 10, 2025

An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsSystemic Lupus Erythematosus Tagged with:abataceptCAR-T cell therapyEuropean Congress of Internal MedicineGiant Cell ArteritisGlucocorticoidsInterstitial Lung DiseaseMethotrexatenintedanibPolymyalgia Rheumaticarituximabserological testingstem cell transplantationSystemic sclerosis

New Study: Upadacitinib Is Treatment Option for Giant Cell Arteritis

Deborah Levenson  |  July 10, 2025

Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesResearch RheumVasculitis Tagged with:AAV FocusRheumActemraGCAGiant Cell ArteritisGlucocorticoidsJAK inhibitorsJanus Kinase InhibitorsprednisoneRINVOQtocilizumabupadacitinib

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 70
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences